Skip to main content

Advertisement

SpringerLink
Log in

Metabolic abnormalities in HIV-infected patients: An update

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

In recent years, substantial progress has been made in our understanding of the pathogenesis, risk factors, and treatment of glucose and lipid abnormalities in HIV-infected patients. Newer antiretrovirals, such as abacavir and tenofovir in the nucleoside reverse transcriptase class and atazanavir in the protease inhibitor class, have been shown to improve metabolic profiles compared to other medications. In addition, new information regarding the efficacy of glucose and lipid-lowering medications in HIV-infected patients has become available. It has also been demonstrated that aggressive risk factor modification can reduce the burden of cardiovascular disease in this population. This article reviews these recent advances in order to help providers respond to these important clinical challenges.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Young J, Weber R, Rickenbach M, et al.: Lipid profiles for antiretroviral-naive patients starting PI-and NNRTI-based therapy in the Swiss HIV cohort study. Antivir Ther 2005, 10:585–591.

    PubMed  CAS  Google Scholar 

  2. Cohen C, Nieto-Cisneros L, Zala C, et al.: Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial. Curr Med Res Opin 2005, 21:1683–1692.

    Article  PubMed  CAS  Google Scholar 

  3. Wood R, Phanuphak P, Cahn P, et al.: Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004, 36:684–692.

    Article  PubMed  CAS  Google Scholar 

  4. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al.:Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005, 39:174–180.

    PubMed  Google Scholar 

  5. Johnson M, Grinsztejn B, Rodriguez C, et al.: 96-week comparison of once-daily atazanavir/ritonavir and twicedaily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006, 20:711–718.

    PubMed  CAS  Google Scholar 

  6. Rodriguez-French A, Boghossian J, Gray GE, et al.: The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr 2004, 35:22–32.

    Article  PubMed  CAS  Google Scholar 

  7. Eron Jr J, Yeni P, Gathe Jr J, et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006, 368:476–482.

    Article  PubMed  CAS  Google Scholar 

  8. Periard D, Telenti A, Sudre P, et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999, 100:700–705.

    PubMed  CAS  Google Scholar 

  9. Malan N, Krantz E, David N, et al.: Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006. Important study to help tease apart the metabolic effects of boosting doses of ritonavir.

  10. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191–201. Landmark study established the efficacy of tenofovir and helped distinguish the effect of tenofovir and stavudine on lipids and bone.

    Article  PubMed  CAS  Google Scholar 

  11. Moyle, G, Sabin, C, Cartledge, J, et al.: A 48-week, randomized open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005. RAVE study, which demonstrates that switches to abacavir or tenofovir from thymidine analogs have equivalent beneficial effects on lipoatrophy, glucose, and lipids.

  12. Schewe CK, Maserati R, Wassmer G, et al.: Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment. Clin Infect Dis 2006, 42:145–147.

    Article  PubMed  CAS  Google Scholar 

  13. da Silva B, Albrecht M, Benson C, et al.: Improved metabolic profile with replacement of stavudine by tenofovir DF after 6 years of a lopinavir/ritonavir-based regimen. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13–17, 2005.

  14. Llibre JM, Domingo P, Perez MJ, et al.: Improvements in dyslipidemia at 48 weeks following substitution of stavudine with tenofovir DF. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13–17, 2005.

  15. Van Der Lee M, Vogel M, Schippers E, et al.: Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  16. Mallon PW, Miller J, Kovacic JC, et al.: Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men—a randomized, placebo-controlled study. AIDS 2006, 20:1003–1010.

    Article  PubMed  CAS  Google Scholar 

  17. Calza L, Manfredi R, Chiodo F: Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002, 30:26–31.

    Article  PubMed  CAS  Google Scholar 

  18. Rao A, D’Amico S, Balasubramanyam A, Maldonado M:Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy. Am J Med Sci 2004, 327:315–318.

    Article  PubMed  Google Scholar 

  19. de Truchis, P: Treatment of hypertriglyceridemia in HIVinfected patients under HAART by polyunsaturated acids: a double blind randomized prospective trial in 122 patients. Presented at the 12th Conference of Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  20. Wohl DA, Tien HC, Busby M, et al.: Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005, 41:1498–1504.

    Article  PubMed  CAS  Google Scholar 

  21. Gerber MT, Mondy KE, Yarasheski KE, et al.: Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Clin Infect Dis 2004, 39:419–425.

    Article  PubMed  CAS  Google Scholar 

  22. Dube MP, Wu JW, Aberg JA, et al.: Safety and Efficacy of Extended-release Niacin for the Treatment of Dyslipidemia in Patients with HIV-infection: a Prospective, Multicenter Study (ACTG 5148). Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13–17, 2005.

  23. Aberg JA, Zackin RA, Brobst SW, et al.: A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005, 21:757–767.

    Article  PubMed  CAS  Google Scholar 

  24. Gerber J, Kitch D, Aberg JA, et al.: The safety and efficacy of fish oil in combination with fenofibrate in subjects on ART with hypertriglyceridemia who had an incomplete response to either agent alone: results of ACTG A5186. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  25. Calza L, Manfredi R, Colangeli V, et al.: Substitution of nevirapine or efavirenz for protease inhibitor versus lipidlowering therapy for the management of dyslipidaemia. AIDS 2005, 19:1051–1058. Investigates whether switching therapy is preferred to lipid-lowering interventions.

    Article  PubMed  CAS  Google Scholar 

  26. Dube MP, Stein JH, Aberg JA, et al.: Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613–627.

    Article  PubMed  Google Scholar 

  27. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune De.c Syndr 2002, 31:257–275.

    Google Scholar 

  28. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752.

    Article  PubMed  Google Scholar 

  29. Nightingale SL: From the Food and Drug Administration. JAMA 1997, 278:379.

    Article  PubMed  CAS  Google Scholar 

  30. Walli R, Herfort O, Michl GM, et al.: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998, 12:F167-F173.

    Article  PubMed  CAS  Google Scholar 

  31. Dube MP: Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000, 31:1467–1475.

    Article  PubMed  CAS  Google Scholar 

  32. Brown TT, Cole SR, Li X, et al.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005, 165:1179–1184.

    Article  PubMed  Google Scholar 

  33. Danoff A, Shi Q, Justman J, et al.: Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. J Acquir Immune Defic Syndr 2005, 39:55–62.

    Article  PubMed  Google Scholar 

  34. American Diabetes Association: Clinical practice recommendations 2004. Diabetes Care 2004, 27(Suppl 1):S1–S150.

  35. Justman JE, Benning L, Danoff A, et al.: Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003, 32:298–302.

    Article  PubMed  CAS  Google Scholar 

  36. Noor MA, Seneviratne T, Aweeka FT, et al.: Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002, 16:F1-F8.

    Article  PubMed  Google Scholar 

  37. Noor MA, Parker RA, O’Mara E, et al.: The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004, 18:2137–2144.

    Article  PubMed  CAS  Google Scholar 

  38. Lee GA, Seneviratne T, Noor MA, et al.: The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004, 18:641–649.

    Article  PubMed  CAS  Google Scholar 

  39. Lee GA, Rao MN, Schwarz JM, et al.: A single dose of amprenavir does not induce insulin resistance in healthy normal volunteers. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13–17, 2005.

  40. ee GA, Mafong DD, Lo JC, et al.: Ritonavir Acutely Induces Insulin Resistance in Healthy Normal Volunteers. Presented at the 6th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Washington, DC; October 25–28, 2004.

  41. Yan Q, Hruz PW: Direct comparison of the acute in vivo effects of HIV protease inhibitors on peripheral glucose disposal. J Acquir Immune Defic Syndr 2005, 40:398–403.

    Article  PubMed  CAS  Google Scholar 

  42. Brown TT, Li X, Cole SR, et al.: Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005, 19:1375–1383.

    Article  PubMed  CAS  Google Scholar 

  43. Mynarcik DC, McNurlan MA, Steigbigel RT, et al.: Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000, 25:312–321.

    Article  PubMed  CAS  Google Scholar 

  44. Shlay JC, Visnegarwala F, Bartsch G, et al.: Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005, 38:147–155.

    Article  PubMed  CAS  Google Scholar 

  45. Blumer RME, van Vonderen MGA, Sutinen J, et al.: Increased lipolysis and reduced peripheral glucose disposal without changes in body composition 3 months after initiating a NRTI-containing, but not a NRTI-sparing regimen in antiretroviral-naïve HIV-1-infected patients: results of a randomized clinical trial. Presented at the 88th Meeting of the Endocrine Society. Boston, MA; June 24–27, 2006.

  46. Ranade K, Parker RA, Ploughman L, et al.: A single nucleotide polymorphism in the resistin gene is associated with adverse metabolic changes on HAART: an exploratory pharmacogenetic association study of A5005s, the metabolic sub-study of ACTG 384. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  47. American Diabetes Association: Clinical practice recommendations. Diabetes Care 2006, 29(Suppl_1):S1-S85.

    Google Scholar 

  48. Hadigan C, Meigs JB, Corcoran C, et al.: Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001, 32:130–139.

    Article  PubMed  CAS  Google Scholar 

  49. Mulligan K, Lo JC, Khatami H, Schambelan M.: Use of the oral glucose tolerance test to estimate insulin sensitivity in patients with HIV-infection. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13–17, 2005.

  50. Diop ME, Bastard JP, Meunier N, et al.: Inappropriate glycated hemoglobin values and hemolysis in HIV-infected patients. Presented at the 7th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Dublin, Ireland; November 13–17, 2005.

  51. Hadigan C, Corcoran C, Basgoz N, et al.: Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA 2000, 284:472–477.

    Article  PubMed  CAS  Google Scholar 

  52. van Wijk JP, de Koning EJ, Cabezas MC, et al.: Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. Ann Intern Med 2005, 143:337–346.

    PubMed  Google Scholar 

  53. Mulligan K, Yang Y, Koletar S, et al.: Effects of metformin and rosiglitazone on body composition in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio: a randomized, placebo-controlled trial. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  54. Kohli R, Wanke C, Gorbach S, Shevitz A: A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  55. Carr A, Workman C, Carey D, et al.: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004, 363:429–438.

    Article  PubMed  CAS  Google Scholar 

  56. Sutinen J, Hakkinen AM, Westerbacka J, et al.:Rosiglitazone in the treatment of HAART-associated lipodystrophy —a randomized double-blind placebo-controlled study. Antivir Ther 2003, 8:199–207.

    PubMed  CAS  Google Scholar 

  57. Hadigan C, Yawetz S, Thomas A, et al.: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004, 140:786–794.

    PubMed  CAS  Google Scholar 

  58. Slama L, Lanoy E, Valentin MA, et al.: Effect of pioglitazone on HIV-1 related lipoatrophy: a randomized double-blind placebo-controlled trial (ANRS 113) with 130 patients. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006. only available study of pioglitazone in HIV-infected patients showing modest improvements in lipoatrophy.

  59. Lebovitz HE, Austin MM, Blonde L, et al.: ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006, 12(Suppl 1):6–12.

    PubMed  Google Scholar 

  60. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143–3421.

  61. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289–2304. Important critique of the metabolic syndrome as a concept.

    Article  PubMed  Google Scholar 

  62. Jerico C, Knobel H, Montero M, et al.: Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care 2005, 28:132–137.

    Article  PubMed  Google Scholar 

  63. Bonfanti P, Ricci E, de Socio G, et al.: Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study. J Acquir Immune Defic Syndr 2006, 42:128–131.

    Article  PubMed  Google Scholar 

  64. Mondy K, Tong S, Kessels L, et al.: Metabolic syndrome in HIV within a representative U.S. patient population. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  65. Palella F, Wang Z, Chu H, et al.: Correlates of the metabolic syndrome among HIV seropositive and seronegative men in the multicenter AIDS cohort study. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  66. Friis-Møller N, Reiss P, El-Sadr W, et al.: Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D Study. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006. Recent update from the landmark study establishing the risk of cardiovascular disease in HIV-infected patients.

  67. Lichtenstein K, Armon C, Buchacz K, et al.: Analysis of cardiovascular risk factors in the HIV outpatient study cohort. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  68. Currier J, Kendall M, Henry K, et al.: 3-year Follow-up of carotid intima-media thickness in HIV-infected and uninfected adults: ACTG 5078. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

Download references

Author information

Authors and Affiliations

  1. 1830 East Monument Street, Suite 333, 21287, Baltimore, MD, USA

    Todd T. Brown MD

Authors
  1. Todd T. Brown MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Cofrancesco Jr MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Todd T. Brown MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brown, T.T., Cofrancesco, J. Metabolic abnormalities in HIV-infected patients: An update. Curr Infect Dis Rep 8, 497–504 (2006). https://doi.org/10.1007/s11908-006-0025-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-006-0025-5

Keywords

Search

Navigation